Our understanding of how FOXM1 inhibitors suppress breast cancer growth and aggressiveness and how breast cancer cells can defeat their effectiveness and acquire resistance should be helpful in directing further studies to move these agents towards translation into the clinic. Here, FOXM1 is linked to breast carcinoma.